{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:58:28Z","timestamp":1757311108189,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Liver disorders are important adverse effects associated with antifungal drug treatment. However, the accuracy of Clinical International Classification of Diseases (ICD)-10 codes in identifying liver disorders for register based research is not well-established. This study aimed to determine the positive predictive value (PPV) of the ICD-10 codes for identifying patients with toxic liver disease, hepatic failure, and jaundice among patients with systemic antifungal treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from the Swedish Prescribed Drug Register and the National Patient Register were utilized to identify adult patients who received systemic azole\u00a0antifungal drugs and had a recorded diagnosis of toxic liver disease (K71.0, K71.1, K71.2, K71.6, K71.8, K71.9), hepatic failure (K72.0, K72.9), or jaundice (R17) between 2005 and 2016. The medical records of all included patients were reviewed. Prespecified criteria were used to re-evaluate and confirm each diagnosis, serving as the gold standard to calculate PPVs with 95% confidence intervals (95% CI) for each diagnostic group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 115 included patients, 26 were diagnosed with toxic liver disease, 58 with hepatic failure, and 31 with jaundice. Toxic liver disease was confirmed in 14 out of 26 patients, yielding a PPV of 53.8% (95% CI 33.4\u201373.4%). Hepatic failure was confirmed in 26 out of 38 patients, resulting in a PPV of 62.1% (95% CI 48.4\u201374.5%). The highest PPV was found in jaundice, with 30 confirmed diagnoses out of 31, yielding a PPV of 96.8% (95% CI 83.3\u201399.9%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Among patients who received azole\u00a0antifungal treatment and were subsequently diagnosed with a liver disorder, the PPV for the diagnosis of jaundice was high, while the PPVs for toxic liver disease and hepatic failure were lower.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-03110-w","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:02:45Z","timestamp":1704499365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Validation of diagnoses of liver disorders in users of systemic azole antifungal medication in Sweden"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8427-6033","authenticated-orcid":false,"given":"Diego Hernan","family":"Giunta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7177-1713","authenticated-orcid":false,"given":"P\u00e4r","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Younus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina Anveden","family":"Berglind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9338-7133","authenticated-orcid":false,"given":"Helle","family":"Kieler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1372-4262","authenticated-orcid":false,"given":"Johan","family":"Reutfors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"3110_CR1","first-page":"w14281","volume":"146","author":"Y Schmiedel","year":"2016","unstructured":"Schmiedel Y, Zimmerli S. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and pneumocystis pneumonia. Swiss Med Wkly. 2016;146:w14281.","journal-title":"Swiss Med Wkly."},{"issue":"2","key":"3110_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijantimicag.2016.10.019","volume":"49","author":"P Koehler","year":"2017","unstructured":"Koehler P, et al. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA study. Int J Antimicrob Agents. 2017;49(2):218\u201323.","journal-title":"Int J Antimicrob Agents."},{"issue":"8","key":"3110_CR3","first-page":"1068","volume":"91","author":"L Pagano","year":"2006","unstructured":"Pagano L, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068\u201375.","journal-title":"Haematologica."},{"issue":"Suppl 4","key":"3110_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1469-0691.2008.01978.x","volume":"14","author":"M Richardson","year":"2008","unstructured":"Richardson M, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;14(Suppl 4):5\u201324.","journal-title":"Clin Microbiol Infect."},{"issue":"4","key":"3110_CR5","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S0891-5520(02)00043-0","volume":"16","author":"BH Segal","year":"2002","unstructured":"Segal BH, Bow EJ, Menichetti F. Fungal infections in nontransplant patients with hematologic malignancies. Infect Dis Clin N Am. 2002;16(4):935\u201364 vii.","journal-title":"Infect Dis Clin N Am."},{"issue":"2","key":"3110_CR6","first-page":"149","volume":"16","author":"I Kyriakidis","year":"2017","unstructured":"Kyriakidis I, et al. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf. 2017;16(2):149\u201365.","journal-title":"Expert Opin Drug Saf."},{"issue":"7","key":"3110_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/myc.12768","volume":"61","author":"SJ Lachenmayr","year":"2018","unstructured":"Lachenmayr SJ, et al. Antifungal treatment in haematological and oncological patients: need for quality assessment in routine care. Mycoses. 2018;61(7):464\u201371.","journal-title":"Mycoses."},{"key":"3110_CR8","doi-asserted-by":"publisher","first-page":"697330","DOI":"10.3389\/fphar.2021.697330","volume":"12","author":"YL Yang","year":"2021","unstructured":"Yang YL, et al. Adverse effects associated with currently commonly used antifungal agents: a network Meta-analysis and systematic review. Front Pharmacol. 2021;12:697330.","journal-title":"Front Pharmacol."},{"issue":"11","key":"3110_CR9","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/ctr.12834","volume":"30","author":"MT Levine","year":"2016","unstructured":"Levine MT, Chandrasekar PH. Adverse effects of voriconazole: over a decade of use. Clin Transpl. 2016;30(11):1377\u201386.","journal-title":"Clin Transpl."},{"issue":"5","key":"3110_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMra021844","volume":"349","author":"WM Lee","year":"2003","unstructured":"Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474\u201385.","journal-title":"N Engl J Med."},{"issue":"6","key":"3110_CR11","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver, Electronic address, e.e.e, et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222\u201361.","journal-title":"J Hepatol."},{"issue":"3","key":"3110_CR12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/hep.25551","volume":"55","author":"WM Lee","year":"2012","unstructured":"Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases position paper on acute liver failure 2011. Hepatology. 2012;55(3):965\u20137.","journal-title":"Hepatology."},{"issue":"1","key":"3110_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cld.2008.10.001","volume":"13","author":"SJ Munoz","year":"2009","unstructured":"Munoz SJ, Stravitz RT, Gabriel DA. Coagulopathy of acute liver failure. Clin Liver Dis. 2009;13(1):95\u2013107.","journal-title":"Clin Liver Dis."},{"issue":"7","key":"3110_CR14","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1111\/j.1572-0241.2001.03964.x","volume":"96","author":"AT Blei","year":"2001","unstructured":"Blei AT, C\u00f3rdoba J, Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol. 2001;96(7):1968\u201376.","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"3110_CR15","first-page":"164","volume":"95","author":"MV Fargo","year":"2017","unstructured":"Fargo MV, Grogan SP, Saguil A. Evaluation of jaundice in adults. Am Fam Physician. 2017;95(3):164\u20138.","journal-title":"Am Fam Physician."},{"issue":"6","key":"3110_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/cpt.857","volume":"102","author":"JM Franklin","year":"2017","unstructured":"Franklin JM, Schneeweiss S. When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol Ther. 2017;102(6):924\u201333.","journal-title":"Clin Pharmacol Ther."},{"key":"3110_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2147\/CLEP.S341480","volume":"14","author":"C Thor Petersen","year":"2022","unstructured":"Thor Petersen C, et al. Mapping outcomes and registries used in current Danish Pharmacoepidemiological research. Clin Epidemiol. 2022;14:521\u201342.","journal-title":"Clin Epidemiol."},{"issue":"4","key":"3110_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40264-019-00903-5","volume":"43","author":"A Yeboah-Korang","year":"2020","unstructured":"Yeboah-Korang A, et al. Utility of a computerized ICD-10 algorithm to identify idiosyncratic drug-induced liver injury cases in the electronic medical record. Drug Saf. 2020;43(4):371\u20137.","journal-title":"Drug Saf."},{"issue":"7","key":"3110_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/pds.3774","volume":"24","author":"V Lo Re 3rd","year":"2015","unstructured":"Lo Re V 3rd, et al. Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiol Drug Saf. 2015;24(7):676\u201383.","journal-title":"Pharmacoepidemiol Drug Saf."},{"doi-asserted-by":"crossref","unstructured":"Louissaint J, et al. Combining K-72 hepatic failure with 15 individual T-codes to identify patients with idiosyncratic drug-induced liver injury in the electronic medical record. Dig Dis Sci. 2021;67.","key":"3110_CR20","DOI":"10.1007\/s10620-021-07223-8"},{"key":"3110_CR21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health."},{"unstructured":"ICD-10 Classification. Available from: https:\/\/www.socialstyrelsen.se\/en\/.","key":"3110_CR22"},{"issue":"7","key":"3110_CR23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, et al. The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf."},{"unstructured":"ATC\/DDD Index 2021. Available from: https:\/\/www.whocc.no\/atc_ddd_index\/.","key":"3110_CR24"},{"issue":"11","key":"3110_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","volume":"24","author":"JF Ludvigsson","year":"2009","unstructured":"Ludvigsson JF, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659\u201367.","journal-title":"Eur J Epidemiol."},{"unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012\u2013. Roussel Uclaf Causality Assessment Method (RUCAM) in Drug Induced Liver Injury. 2019. PMID: 31689029.\u00a0Bookshelf ID: NBK548272.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/31689029\/,\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548272\/.","key":"3110_CR26"},{"issue":"1","key":"3110_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/jhep.2001.20645","volume":"33","author":"MI Lucena","year":"2001","unstructured":"Lucena MI, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33(1):123\u201330.","journal-title":"Hepatology."},{"issue":"4","key":"3110_CR28","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/hep.22442","volume":"48","author":"J Rochon","year":"2008","unstructured":"Rochon J, et al. Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology. 2008;48(4):1175\u201383.","journal-title":"Hepatology."},{"issue":"6","key":"3110_CR29","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/hep.23577","volume":"51","author":"DC Rockey","year":"2010","unstructured":"Rockey DC, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51(6):2117\u201326.","journal-title":"Hepatology."},{"issue":"2","key":"3110_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00001503-200004000-00005","volume":"13","author":"W Bernal","year":"2000","unstructured":"Bernal W, Wendon J. Acute liver failure. Curr Opin Anaesthesiol. 2000;13(2):113\u20138.","journal-title":"Curr Opin Anaesthesiol."},{"issue":"4","key":"3110_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"P Tabarsi","year":"1934","unstructured":"Tabarsi P, Clopper ESPCJ. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404\u201313.","journal-title":"Biometrika."},{"key":"3110_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev-publhealth-031210-100700","volume":"32","author":"DP Jutte","year":"2011","unstructured":"Jutte DP, Roos LL, Brownell MD. Administrative record linkage as a tool for public health research. Annu Rev Public Health. 2011;32:91\u2013108.","journal-title":"Annu Rev Public Health."},{"issue":"4","key":"3110_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40263-019-00611-9","volume":"33","author":"M Pladevall-Vila","year":"2019","unstructured":"Pladevall-Vila M, et al. Risk of acute liver injury in Agomelatine and other antidepressant users in four European countries: a cohort and nested case-control study using automated health data sources. CNS Drugs. 2019;33(4):383\u201395.","journal-title":"CNS Drugs."},{"issue":"7","key":"3110_CR34","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/pds.4803","volume":"28","author":"J Forns","year":"2019","unstructured":"Forns J, et al. Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: a study in three European data sources. Pharmacoepidemiol Drug Saf. 2019;28(7):965\u201375.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"10","key":"3110_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/pds.4855","volume":"28","author":"A Timmer","year":"2019","unstructured":"Timmer A, et al. Validity of hospital ICD-10-GM codes to identify acute liver injury in Germany. Pharmacoepidemiol Drug Saf. 2019;28(10):1344\u201352.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"11","key":"3110_CR36","first-page":"1190","volume":"43","author":"Y Reisman","year":"1996","unstructured":"Reisman Y, et al. Clinical presentation of (subclinical) jaundice--the Euricterus project in The Netherlands. United Dutch Hospitals and Euricterus Project Management Group. Hepatogastroenterology. 1996;43(11):1190\u20135.","journal-title":"Hepatogastroenterology."},{"issue":"8","key":"3110_CR37","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/emermed-2019-208447","volume":"36","author":"B Kea","year":"2019","unstructured":"Kea B, Hall MK, Wang R. Recognising bias in studies of diagnostic tests part 2: interpreting and verifying the index test. Emerg Med J. 2019;36(8):501\u20135.","journal-title":"Emerg Med J."},{"issue":"11","key":"3110_CR38","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323\u201330.","journal-title":"J Clin Epidemiol."},{"issue":"11","key":"3110_CR39","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","volume":"46","author":"C Benichou","year":"1993","unstructured":"Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331\u20136.","journal-title":"J Clin Epidemiol."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03110-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-03110-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03110-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T12:03:05Z","timestamp":1704542585000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-03110-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3110"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-03110-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"type":"electronic","value":"1471-230X"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki. The study protocol was approved by the Regional Ethical Board in Stockholm (2016\/397\u201331). This research was part of the Post-Authorization Safety Study (PASS) titled \u201cAn Active Safety Surveillance Program to Monitor Selected Events in Patients with Long-Term Voriconazole Use\u201d (protocol number A1501103), and was registered under EUPAS12624. Written informed consent, granting access to each specific medical record, was obtained from the responsible heads of each clinic accountable for the treatment of the patients and their medical records. Considering the retrospective nature of the study, the ethics committee waived the requirement for written informed consent from the patients. The medical records and the data were maintained confidentially and accessed only by the research team for the purpose of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DHG, PK, HK and JR are employees at the Centre for Pharmacoepidemiology, which receives grants from several entities (pharmaceutical companies, regulatory authorities and contract research organizations) for the performance of drug safety and drug utilization studies, unrelated to this work.MY is an employee and own stocks in Pfizer Inc.IAB has no competing interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}